GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...
The results further undermine Relvar Ellipta, which is already struggling to establish itself in the COPD market. The drug is positioned as a follow-up product to GSK’s blockbuster Advair ...
After hours: March 13 at 7:58:06 PM EDT Loading Chart for GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback